|
EP1542997B1
(de)
|
2002-07-24 |
2012-02-29 |
Dermira (Canada), Inc. |
Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
|
|
EP1606266A4
(de)
*
|
2003-03-21 |
2008-06-25 |
Smithkline Beecham Corp |
Chemische verbindungen
|
|
AR045134A1
(es)
*
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
|
JP4692281B2
(ja)
*
|
2003-08-05 |
2011-06-01 |
味の素株式会社 |
新規アゾール化合物
|
|
JP4764823B2
(ja)
*
|
2003-10-06 |
2011-09-07 |
グラクソ グループ リミテッド |
キナーゼ阻害剤としての1,6−二置換アザベンゾイミダゾールの調製
|
|
WO2005034866A2
(en)
*
|
2003-10-06 |
2005-04-21 |
Glaxo Group Limited |
Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
|
|
WO2005037198A2
(en)
*
|
2003-10-06 |
2005-04-28 |
Glaxo Group Limited |
Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
|
|
TW200538453A
(en)
*
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
|
CN101083985A
(zh)
|
2004-09-21 |
2007-12-05 |
幸讬制药公司 |
用于炎症及免疫相关用途的化合物
|
|
CA2584170C
(en)
*
|
2004-10-13 |
2013-08-20 |
Wolfgang Staehle |
Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases
|
|
ZA200704888B
(en)
*
|
2004-11-22 |
2009-02-25 |
Vertex Pharma |
Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
|
|
EP1848696A1
(de)
*
|
2005-01-21 |
2007-10-31 |
Schering Corporation |
Als histamin-h3-antagonisten geeignete imidazol- und benzimidazolderivate
|
|
CR9465A
(es)
*
|
2005-03-25 |
2008-06-19 |
Surface Logix Inc |
Compuestos mejorados farmacocineticamente
|
|
TW200716110A
(en)
*
|
2005-04-20 |
2007-05-01 |
Smithkline Beecham Corp |
Inhibitors of AKT activity
|
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
|
US20090215857A1
(en)
*
|
2005-09-13 |
2009-08-27 |
Pfizer Products Inc. |
Therapeutic Pyrrolidines
|
|
US7625890B2
(en)
|
2005-11-10 |
2009-12-01 |
Smithkline Beecham Corp. |
Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
|
|
EP1956013B1
(de)
|
2005-11-30 |
2016-04-13 |
Fujifilm RI Pharma Co., Ltd. |
Diagnostikum und heilmittel für eine durch amyloidaggregation und/oder ablagerung verursachte krankheit
|
|
JP2009521494A
(ja)
*
|
2005-12-22 |
2009-06-04 |
アルコン リサーチ, リミテッド |
rhoキナーゼ媒介性疾患および状態を治療するための(インダゾール−5−イル)−ピラジンおよび(1,3−ジヒドロインドール−2−オン)−ピラジン
|
|
US8227603B2
(en)
*
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
|
DK2069352T5
(en)
*
|
2006-08-02 |
2017-04-03 |
Cytokinetics Inc |
SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES
|
|
US8299248B2
(en)
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
|
FR2910473B1
(fr)
|
2006-12-26 |
2009-02-13 |
Sanofi Aventis Sa |
Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
|
|
UY30892A1
(es)
*
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
|
EP2139478A4
(de)
*
|
2007-03-30 |
2010-05-05 |
Cytokinetics Inc |
Bestimmte chemische entitäten, zusammensetzungen und verfahren
|
|
JP2011500778A
(ja)
|
2007-10-25 |
2011-01-06 |
アストラゼネカ・アクチエボラーグ |
ピリジン及びピラジン誘導体−083
|
|
CN101983061A
(zh)
*
|
2008-02-04 |
2011-03-02 |
赛特凯恩蒂克公司 |
某种化学物质、组合物和方法
|
|
CA2723852A1
(en)
*
|
2008-05-16 |
2009-11-19 |
Cellzome Ag |
Methods for the identification of parp interacting molecules and for the purification of parp proteins
|
|
JP5702293B2
(ja)
|
2008-11-10 |
2015-04-15 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な化合物
|
|
BRPI0924084B1
(pt)
|
2008-12-19 |
2021-12-21 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina e composição farmacêutica que os compreende
|
|
WO2010083145A1
(en)
*
|
2009-01-16 |
2010-07-22 |
Merck Sharp & Dohme Corp. |
IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
|
|
CA2750565C
(en)
*
|
2009-01-30 |
2015-10-20 |
Glaxosmithkline Llc |
Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
|
|
EP2398897B1
(de)
|
2009-02-20 |
2017-06-28 |
Cellular Dynamics International, Inc. |
Verfahren und zusammensetzungen zur differenzierung von stammzellen
|
|
CN102388130B
(zh)
|
2009-02-27 |
2014-08-27 |
细胞动力国际有限公司 |
多能细胞的分化
|
|
WO2011034741A1
(en)
*
|
2009-09-15 |
2011-03-24 |
Merck Sharp & Dohme Corp. |
Imidazopyridin-2-one derivatives
|
|
MX2012007367A
(es)
*
|
2009-12-30 |
2013-04-03 |
Arqule Inc |
Compuestos substituidos de imidazopiridinilo-aminopiridina.
|
|
WO2011143422A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
2 -aminopyridine derivatives useful as inhibitors of atr kinase
|
|
AU2011253025A1
(en)
|
2010-05-12 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2569287B1
(de)
|
2010-05-12 |
2014-07-09 |
Vertex Pharmaceuticals Inc. |
Verbindungen als hemmer der atr-kinase
|
|
US9062008B2
(en)
|
2010-05-12 |
2015-06-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8962631B2
(en)
|
2010-05-12 |
2015-02-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2013526538A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
WO2011163527A1
(en)
|
2010-06-23 |
2011-12-29 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
|
|
US9279106B2
(en)
|
2010-11-12 |
2016-03-08 |
Georgetown University |
Immortalization of epithelial cells and methods of use
|
|
WO2012138938A1
(en)
|
2011-04-05 |
2012-10-11 |
Vertex Pharmaceuticals Incorporated |
Aminopyrazine compounds useful as inhibitors of tra kinase
|
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
EP2723745A1
(de)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Als art-kinasehemmer nützliche verbindungen
|
|
JP2014522818A
(ja)
|
2011-06-22 |
2014-09-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
EP2723741B8
(de)
|
2011-06-24 |
2016-09-21 |
ArQule, Inc. |
Substituierte imidazopyridinyl-aminopyridin-verbindungen
|
|
WO2012177852A1
(en)
|
2011-06-24 |
2012-12-27 |
Arqule, Inc |
Substituted imidazopyridinyl compounds
|
|
CN102295594B
(zh)
*
|
2011-07-12 |
2016-01-20 |
上海医药工业研究院 |
4-n-取代-1-(3-甲氧基丙基)-4-哌啶胺类化合物及制备和应用
|
|
US10272082B2
(en)
|
2011-07-13 |
2019-04-30 |
Cytokinetics, Inc. |
Combination ALS therapy
|
|
MX2014003796A
(es)
|
2011-09-30 |
2015-01-16 |
Vertex Pharma |
Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
|
|
WO2013049719A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013049720A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
IN2014CN02501A
(de)
|
2011-09-30 |
2015-06-26 |
Vertex Pharma |
|
|
SG10201606774UA
(en)
|
2011-09-30 |
2016-10-28 |
Vertex Pharma |
Processes for making compounds useful as inhibitors of atr kinase
|
|
EP2776421A1
(de)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinasehemmer nützliche verbindungen
|
|
EP2776422A1
(de)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinasehemmer nützliche verbindungen
|
|
US8841449B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2776429A1
(de)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinaseinhibitoren nützliche verbindungen
|
|
WO2013071093A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
|
US20140044802A1
(en)
|
2012-04-05 |
2014-02-13 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
and combination therapies thereof
|
|
US9260696B2
(en)
|
2012-04-24 |
2016-02-16 |
Dan S. Kaufman |
Method for developing natural killer cells from stem cells
|
|
KR20150060724A
(ko)
*
|
2012-09-28 |
2015-06-03 |
머크 샤프 앤드 돔 코포레이션 |
Erk 억제제인 신규 화합물
|
|
EP2900223B1
(de)
|
2012-09-28 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Neuartige verbindungen als erk-hemmer
|
|
DK2904406T3
(en)
|
2012-10-04 |
2018-06-18 |
Vertex Pharma |
METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
|
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
SMT202000713T1
(it)
|
2012-12-07 |
2021-03-15 |
Vertex Pharma |
Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
|
|
GB201304526D0
(en)
*
|
2013-03-13 |
2013-04-24 |
Proximagen Ltd |
New compounds
|
|
JP6433974B2
(ja)
|
2013-03-14 |
2018-12-05 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Jak2およびalk2阻害剤およびその使用方法
|
|
CA2899507A1
(en)
|
2013-03-14 |
2014-09-25 |
The Regents Of The University Of California |
In vitro production of medial ganglionic eminence precursor cells
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
MX360455B
(es)
|
2013-05-14 |
2018-11-01 |
Active Biotech Ab |
Derivados de n-(heteroaril)-sulfonamida utiles como inhibidores de s100.
|
|
EP3046557A1
(de)
|
2013-09-20 |
2016-07-27 |
Stichting Het Nederlands Kanker Instituut |
Rock in kombination mit mapk-signalweg
|
|
HUE046727T2
(hu)
|
2013-12-06 |
2020-03-30 |
Vertex Pharma |
Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
|
|
SG11201608722QA
(en)
*
|
2014-04-22 |
2016-11-29 |
Arqule Inc |
Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
|
|
CN107074863B
(zh)
|
2014-06-05 |
2019-12-03 |
沃泰克斯药物股份有限公司 |
Atr激酶抑制剂的制备方法及其不同的固体形式
|
|
PL3157566T3
(pl)
|
2014-06-17 |
2019-10-31 |
Vertex Pharma |
Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
|
|
KR20170020527A
(ko)
|
2014-06-27 |
2017-02-22 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
배양된 포유동물 윤부 줄기세포, 이를 생성하는 방법, 및 이의 용도
|
|
AU2015353853B2
(en)
|
2014-11-25 |
2020-10-15 |
President And Fellows Of Harvard College |
Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
|
|
EP3277799B1
(de)
|
2015-04-03 |
2020-09-23 |
Propagenix Inc. |
Ex-vivo-proliferation von epithelzellen
|
|
US10100285B2
(en)
|
2015-04-03 |
2018-10-16 |
Propagenix Inc. |
Ex vivo proliferation of epithelial cells
|
|
EP3892718A1
(de)
|
2015-09-11 |
2021-10-13 |
Propagenix Inc. |
Ex-vivo-proliferation von epithelzellen
|
|
KR102678021B1
(ko)
|
2015-09-30 |
2024-06-26 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
|
|
US20180305334A1
(en)
*
|
2015-10-14 |
2018-10-25 |
Aquinnah Pharmaceuticals, Inc. |
Compounds, compositions and methods of use against stress granules
|
|
US20190060286A1
(en)
|
2016-02-29 |
2019-02-28 |
University Of Florida Research Foundation, Incorpo |
Chemotherapeutic Methods
|
|
US20200385406A1
(en)
*
|
2017-12-22 |
2020-12-10 |
Southern Research Institute |
Substituted heterocyclic-pyridinones as hiv-1 nef-hck inhibitors
|
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
CA3107502A1
(en)
|
2018-08-20 |
2020-02-27 |
Chengkang ZHANG |
Epithelial cell spheroids
|
|
US12281308B2
(en)
|
2018-08-29 |
2025-04-22 |
University Of Massachusetts |
Inhibition of protein kinases to treat Friedreich ataxia
|
|
PT3860998T
(pt)
|
2018-10-05 |
2024-04-02 |
Annapurna Bio Inc |
Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
|
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
|
CN111732584B
(zh)
*
|
2019-03-25 |
2024-02-27 |
复旦大学 |
二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
|
|
US20230348852A1
(en)
|
2020-04-27 |
2023-11-02 |
Novartis Ag |
Methods and compositions for ocular cell therapy
|
|
JP2024538174A
(ja)
|
2021-10-18 |
2024-10-18 |
エヴィア ライフ サイエンシズ インコーポレイテッド |
肝線維症を処置するための組成物およびその使用方法
|
|
US20250235484A1
(en)
|
2021-10-22 |
2025-07-24 |
Evia Life Sciences Inc. |
Methods for making extracellular vesicles, and compositions and methods of use thereof
|
|
CN120092008A
(zh)
*
|
2022-10-20 |
2025-06-03 |
上海瑛派药业有限公司 |
取代的杂芳基双环化合物作为usp1抑制剂及其应用
|
|
KR20250113344A
(ko)
*
|
2024-01-17 |
2025-07-25 |
주식회사 엘지화학 |
CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물
|
|
CN119235877B
(zh)
*
|
2024-11-08 |
2025-11-11 |
中山大学 |
一种钌(iii)酸盐的组合物及其应用
|